The company's drug discovery platform utilizes human antibodies and cytokine responses obtained from the natural human immune response to identify new antibodies and antigens for commercialization. Their technology portfolio is based on the innate capabilities and selectivity of the immune system, enabling the development of safe, non-toxic, and specific biological drugs for use in the clinic. Nascent Biotech's products include Pritumumab, CLNH5, and MultiPharm, with a focus on the development of Pritumumab for the treatment of brain and pancreatic cancers. The company's clinical premise is to modulate the human body's natural ability to generate an immune response through monoclonal antibodies and cytokines, which have become the fastest-growing products in the pharmaceutical industry.